title: Phase 1/2 study of blinatumomab in relapsed paediatric ALL.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000367:Age Factors; D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D000074322:Antineoplastic Agents, Immunological; C510808:blinatumomab